DENVER, Aug. 28, 2014 /PRNewswire/ -- Pharmatech initiated enrollment for its AccessPPM program after a two-year investment into this game-changing method for matching cancer patients to cancer clinical trials.
Today, clinical trials target specific cancers, disease staging, and genetic mutations - which may be contributing factors for the cancer, in the first place. The challenge that the industry faces, is that this information may not be well known to the patient or even their treating oncologist. Utilizing the Paradigm Cancer Diagnostic (PCDx) molecular profiling and patients' treatment history. AccessPPM patients have their tumor biopsy analyzed for the expression of certain biomarkers and are correctly matched to the correlating study best suited for their disease.
Rob Bohacs, CEO of Pharmatech, commented, "We are sincerely pleased to begin the enrollment phase of this program and begin matching patients with clinical trials at a genetic level. The evolution of research today is transforming and research is accelerating, but there is a disconnect between patients' understanding of their disease and the complexity of clinical trials. Clinical trials are being designed to target mutations at a cellular level and that complexity challenges the ability to match patients to the right study. AccessPPM will change the way patients access clinical trials and will help pharmaceutical companies identify patients that are interested in research."
The comprehensive molecular testing will be performed by Paradigm at their commercial laboratory at the University of Michigan. The Paradigm PCDx test evaluates over 500 molecular abnormalities and delivers those results in one week to the treating physician. The test evaluates the known, clinically actionable mutations for solid tumor malignancies, and provides specific associations for potential FDA approved therapies and investigational treatments.
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization and Contract Research Organization exclusively focused on oncology clinical research. Through a large organized network of cancer clinics, Pharmatech is able to focus on a unique patient-centric approach of clinical trial enrollment and on promoting cancer patient care through the inclusion of clinical trials in a spectrum of patient treatment options for pharmaceutical companies.
Paradigm, a non-profit corporation, brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients. Through Next-Gen Sequencing, Paradigm is able to provide information about the genomic landscape of a patient's cancer and potential therapies, based on the characterization of the patient's tumor.
SOURCE Pharmatech, Inc.